One cGMP decision.
Defensible.
Before you spend $297, read two complete Inspection Response Records. Real format. Fictitious scenarios. The same structured output you'll receive for your own decision — delivered within 24 hours of submission.
Seven structured sections. One defensible record.
The investigator's question, answered in 2–4 sentences. No filler, no boilerplate.
Who made the decision, their title, and when. Gaps named explicitly.
Each piece of evidence the authorizer considered at the moment of decision.
Why the decision was defensible given the evidence available.
The specific regulation the decision aligns with (21 CFR 211 or 21 CFR 820).
Remaining uncertainty or accepted residual risk at the moment of authorization.
Every documentation gap surfaced, labeled by severity (red/amber), with the specific inspector exposure each one creates.
PDF + editable text. Your name and title entered as the authorizing party. Dated and ready to file.
Every section is derived strictly from what you submit. No fabricated evidence. No invented authorization trails. If a gap exists, the record names it — because that's what makes the record defensible.
See it applied to two real cGMP decisions.
Both scenarios are fictitious. Both are representative of decisions pharmaceutical and medical device quality teams face every week. Toggle between them to see how the same structure handles different decision types.
Event: In-process deviation during tablet compression of Lot 24-0418-A on 18-Apr-2024. Tablet hardness readings for Stage 2 recorded 8.2 kP against validated specification of 9.0–12.0 kP across three composite samples over 12 minutes of production. Excursion identified during routine in-process testing. Root cause investigation (DEV-2024-0318): Pre-compression roll pressure drift attributed to wear on compression tooling. Tooling replaced same-shift. Post-replacement samples returned to specification. Impact assessment: QC ran dissolution and content uniformity on samples from the affected 12-minute window. Both parameters met specification. Stability risk evaluated by formulation sciences — no impact expected based on dissolution data. CAPA initiated (CAPA-2024-0092) — compression tooling inspection frequency increased from monthly to bi-weekly. Batch disposition: Released. QA review of deviation investigation, impact assessment, and CAPA complete. QP signed Annex 16 release statement. Authorizing party: Dr. Priya Patel, Qualified Person. Decision date: 25-Apr-2024.
Who authorized release and on what basis
Dr. Priya Patel, Qualified Person, authorized the release of Lot 24-0418-A on 25-Apr-2024 following a 12-minute tablet hardness deviation during Stage 2 compression. The authorization relied on supplementary dissolution and content uniformity testing (both within specification) and a formulation sciences impact assessment concluding no stability risk. However, the record does not document the specific written procedure governing batch release with in-process specification deviations, and does not reference the QP's written authority to accept deviation-based release under 21 CFR 211.22 and 211.100.
Decision owner and timestamp
Dr. Priya Patel, Qualified Person. Decision date: 25-Apr-2024. Authorization captured via Annex 16 release statement. The record does not separate the timestamp of the QP's review of the deviation investigation and impact assessment from the timestamp of release authorization — under inspection, these are expected to be discrete, auditable events.
What the authorizer considered
- In-process tablet hardness records — Stage 2, three composite samples, 12-minute excursion window
- Deviation investigation DEV-2024-0318 — root cause: compression tooling wear
- QC dissolution results — within specification
- Content uniformity results — within specification
- Formulation sciences stability impact assessment — no expected impact
- CAPA-2024-0092 — compression tooling inspection frequency change
Why the decision was justified at the time
The QP concluded that despite the in-process hardness deviation, supplementary quality attributes critical to product performance (dissolution, content uniformity) met specification, and formulation sciences assessed no stability risk. The CAPA addresses the root cause to prevent recurrence. The justification does not reference a written deviation release procedure or document alternative batch dispositions (e.g., partial release, rework, rejection) as considered and rejected by the QP before authorizing full release.
21 CFR 211 · cGMP
The decision falls under 21 CFR 211.22 (responsibilities of the quality control unit), 21 CFR 211.100 (written procedures; deviations), and 21 CFR 211.192 (production record review). Release of a batch following an in-process specification deviation is a recognized pathway when (a) a written deviation procedure authorizes the practice, (b) product quality impact is demonstrably assessed, and (c) the QP formally authorizes release on the documented evidence. Elements (b) and (c) are evidenced in the record; element (a) is not referenced.
Remaining uncertainty at authorization
Residual risk was implicitly accepted based on the dissolution and content uniformity results combined with the formulation sciences assessment. The record does not document residual risk as a formal QP position — specifically, the QP's acknowledgment of any remaining uncertainty about long-term stability given the hardness excursion. Under inspection, the QP would need to articulate what margin of acceptability was present and what residual risk was deemed tolerable.
Documentation gaps this record makes inspection-visible
Event: OOS assay result for active pharmaceutical ingredient in Lot 24-0312-C stability sample at 6-month timepoint. Reported result 94.2% against specification of 95.0–105.0%. Investigation triggered per OOS SOP on 18-Mar-2024. Phase 1 (Laboratory Investigation): Analyst interview identified possible pipetting technique issue during sample preparation. Hypothesis: incomplete transfer of API from weighing boat. Second analyst retest on reserve sample: 99.1% — within specification. Phase 2 (Full Investigation): Original preparation materials recovered and visually inspected — residual powder observed on original weighing boat consistent with incomplete transfer hypothesis. Conclusion: Original result invalidated as laboratory error. Retest result of 99.1% accepted as reportable value. CAPA-2024-0075: Analyst retraining on quantitative transfer technique. Verification testing added to monthly QC round. Investigation closed. Stability trend unchanged. No batch impact. Authorizing party: Dr. James Whitaker, Director of Quality Control. Decision date: 02-Apr-2024.
Who authorized closure and on what basis
Dr. James Whitaker, Director of Quality Control, authorized the closure of OOS-2024-0157 on 02-Apr-2024 as an invalidated laboratory error. The authorization relied on an analyst-interview-based hypothesis (incomplete API transfer), a within-specification retest by a second analyst (99.1%), and visual confirmation of residual powder on the original weighing boat. However, the record does not document the application of FDA OOS guidance criteria for invalidating an original result, and does not capture statistical comparison of the original and retest values as expected under current OOS investigation practice.
Decision owner and timestamp
Dr. James Whitaker, Director of Quality Control. Decision date: 02-Apr-2024. Authorization captured via OOS investigation closure form. The record does not document the QC Director's explicit review of each investigation phase as discrete events — the closure appears as a single signature against the completed form rather than phase-by-phase authorization. FDA OOS guidance treats the decision to invalidate an original result as a distinct, defensible authorization event.
What the authorizer considered
- Original OOS assay result — 94.2% (specification 95.0–105.0%)
- Analyst interview record — pipetting technique hypothesis
- Second-analyst retest result — 99.1%
- Visual inspection of original weighing boat — residual powder observed
- Stability trend data — unchanged
- CAPA-2024-0075 — analyst retraining plan
Why the decision was justified at the time
The QC Director concluded that the original OOS result was attributable to an identified laboratory error (incomplete API transfer) supported by (a) the analyst's own technique hypothesis, (b) the within-specification retest result, and (c) physical evidence of residual powder. The justification does not reference the specific invalidation criteria in FDA OOS guidance, does not document statistical evaluation of the original versus retest value, and does not address whether alternative hypotheses (e.g., genuine product OOS with later sample variability) were evaluated and rejected.
21 CFR 211.192 · FDA OOS Guidance
The decision falls under 21 CFR 211.192 (production record review and investigation of any unexplained discrepancy) and is governed operationally by FDA guidance on OOS investigations (2022). Invalidating an original OOS result as laboratory error is a recognized pathway when (a) a specific, confirmed root cause is identified, (b) the cause is assignable and supported by physical or procedural evidence, and (c) the invalidation is authorized by the appropriate level of QC authority with reference to the OOS guidance criteria. Element (a) and (b) are present; element (c) is partially evidenced — the QC Director authorized closure but the record does not cite guidance criteria.
Remaining uncertainty at authorization
Residual risk is the possibility that the original 94.2% result reflected a genuine product deviation and that the retest variance is explained by sampling. The record does not document the QC Director's formal evaluation of this alternative hypothesis or explain why it was rejected in favor of the laboratory-error attribution. Under inspection, the QC Director would be expected to articulate the basis for this comparative judgment.
Documentation gaps this record makes inspection-visible
One decision. Defensible.
Submit the record for your highest-risk decision — a batch release, a deviation closure, an OOS investigation, a CAPA authorization. You'll receive an Inspection Response Record in this exact format within 24 hours. Gaps flagged. Authorization structured. Ready to file.
Before you buy
What happens after I purchase?
After checkout, you'll receive an email with a secure submission link. You paste your record — the narrative from your batch record, deviation investigation, OOS closure, or CAPA disposition. Within 24 hours, you receive your Inspection Response Record in the format shown above, delivered as both PDF and editable text.
Is this a template, or an actual record?
An actual record, derived strictly from what you submit. No boilerplate. Every section is built from your evidence and your decision logic. Gaps in your submission are named explicitly in the "Known Limitations" section — because that honesty is what makes the record inspection-defensible.
What if my decision has gaps?
The record will surface them. That's the point. An investigator will find gaps either way — you want to see them before they do, so you can decide whether to strengthen the record, escalate internally, or adjust the disposition. The IRR makes your exposure visible to you first.
Can I use this as a legal document?
The IRR is a structured authorization record, not legal counsel. It captures decision logic in the form inspectors look for and in a format that aligns with 21 CFR 211 and 21 CFR 820 expectations. Retention, legal review, and filing within your quality system is your organization's responsibility.
What if I need this for multiple decisions?
The IRR at $297 is designed for one high-risk decision. If you have a recurring pattern — batch releases every week, OOS investigations across multiple products, CAPA authorizations at scale — you want Team Membership, which gives your team the structure continuously rather than one record at a time.